NASDAQ:ADAP Adaptimmune Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adaptimmune Therapeutics PLC - Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.43 -0.32 (-2.98 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$10.18Now: $10.43▼$10.8350-Day Range$7.82MA: $8.50▼$10.7852-Week Range$0.71Now: $10.43▼$13.40Volume535,998 shsAverage Volume694,338 shsMarket Capitalization$1.36 billionP/E RatioN/ADividend YieldN/ABeta2.08 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingAdaptimmune Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.50, Adaptimmune Therapeutics has a forecasted upside of 58.2% from its current price of $10.43.Amount of Analyst CoverageAdaptimmune Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesAdaptimmune Therapeutics has received 292 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAdaptimmune Therapeutics has received 301 “underperform” votes. (Add your “underperform” vote.)Community SentimentAdaptimmune Therapeutics has received 50.76% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Adaptimmune Therapeutics and other stocks. Vote “Outperform” if you believe ADAP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADAP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAdaptimmune Therapeutics does not currently pay a dividend.Dividend GrowthAdaptimmune Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptimmune Therapeutics insiders have sold 75.88% more of their company's stock than they have bought. Specifically, they have bought $53,460.00 in company stock and sold $94,026.00 in company stock.Percentage Held by InsidersOnly 18.89% of the stock of Adaptimmune Therapeutics is held by insiders.Percentage Held by Institutions98.57% of the stock of Adaptimmune Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Adaptimmune Therapeutics are expected to decrease in the coming year, from ($0.91) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptimmune Therapeutics is -9.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptimmune Therapeutics is -9.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptimmune Therapeutics has a P/B Ratio of 8.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADAP Previous Symbol CUSIPN/A CIK1621227 Webwww.adaptimmune.com Phone44-12-3543-0000Debt Debt-to-Equity RatioN/A Current Ratio11.88 Quick Ratio11.88Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.12 million Price / Sales1,211.65 Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book8.84Profitability EPS (Most Recent Fiscal Year)($1.32) Net Income$-137,160,000.00 Net Margins-5,687.30% Return on Equity-58.60% Return on Assets-42.69%Miscellaneous Employees406 Outstanding Shares130,110,000Market Cap$1.36 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $10.43 -0.32 (-2.98 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ADAP News and Ratings via Email Sign-up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Adaptimmune Therapeutics (NASDAQ:ADAP) Frequently Asked Questions How has Adaptimmune Therapeutics' stock price been impacted by COVID-19 (Coronavirus)? Adaptimmune Therapeutics' stock was trading at $2.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADAP shares have increased by 254.8% and is now trading at $10.43. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Adaptimmune Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Adaptimmune Therapeutics. When is Adaptimmune Therapeutics' next earnings date? Adaptimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Adaptimmune Therapeutics. How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) released its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.24) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.24). The biotechnology company had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.95 million. Adaptimmune Therapeutics had a negative return on equity of 58.60% and a negative net margin of 5,687.30%. View Adaptimmune Therapeutics' earnings history. What price target have analysts set for ADAP? 6 equities research analysts have issued twelve-month price objectives for Adaptimmune Therapeutics' shares. Their forecasts range from $5.00 to $42.00. On average, they anticipate Adaptimmune Therapeutics' share price to reach $16.50 in the next twelve months. This suggests a possible upside of 58.2% from the stock's current price. View analysts' price targets for Adaptimmune Therapeutics. Are investors shorting Adaptimmune Therapeutics? Adaptimmune Therapeutics saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 3,250,000 shares, a decline of 18.8% from the August 15th total of 4,000,000 shares. Based on an average daily volume of 799,600 shares, the days-to-cover ratio is currently 4.1 days. View Adaptimmune Therapeutics' Short Interest. Who are some of Adaptimmune Therapeutics' key competitors? Some companies that are related to Adaptimmune Therapeutics include Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Denali Therapeutics (DNLI), Relay Therapeutics (RLAY), Ablynx (ABLYF), Halozyme Therapeutics (HALO), bluebird bio (BLUE), Fate Therapeutics (FATE), Immunovant (IMVT), Twist Bioscience (TWST), Legend Biotech (PCVX), Sorrento Therapeutics (SRNE) and Editas Medicine (EDIT). View all competitors. What other stocks do shareholders of Adaptimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG). Who are Adaptimmune Therapeutics' key executives? Adaptimmune Therapeutics' management team includes the following people: Mr. James Julian Noble, CEO & Director (Age 60)Dr. Helen Katrina Tayton-Martin, Co-Founder & Chief Bus. Officer (Age 52)Mr. Adrian Rawcliffe, Chief Financial Officer (Age 47)Mr. William C. Bertrand Jr., Chief Operating Officer (Age 54)Dr. Rafael Amado, Pres of R&D (Age 55) When did Adaptimmune Therapeutics IPO? (ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager. What is Adaptimmune Therapeutics' stock symbol? Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP." Who are Adaptimmune Therapeutics' major shareholders? Adaptimmune Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RTW Investments LP (2.00%), FMR LLC (1.94%), FMR LLC (1.94%), Victory Capital Management Inc. (1.47%), Avidity Partners Management LP (1.11%) and Rathbone Brothers plc (0.34%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, Elliot Norry, Gavin Wood, Gwendolyn Knowlt Binder-Scholl, James Noble, John Lunger, Lawrence M Alleva, Peter W Sonsini, Rafael Amado and William C Bertrand, Jr. View institutional ownership trends for Adaptimmune Therapeutics. Which institutional investors are selling Adaptimmune Therapeutics stock? ADAP stock was sold by a variety of institutional investors in the last quarter, including WS Management Lllp. Company insiders that have sold Adaptimmune Therapeutics company stock in the last year include Adrian Rawcliffe, Elliot Norry, James Noble, John Lunger, and William C Bertrand, Jr. View insider buying and selling activity for Adaptimmune Therapeutics. Which institutional investors are buying Adaptimmune Therapeutics stock? ADAP stock was acquired by a variety of institutional investors in the last quarter, including RTW Investments LP, Victory Capital Management Inc., Avidity Partners Management LP, FMR LLC, FMR LLC, Goldman Sachs Group Inc., Marshall Wace North America L.P., and Perceptive Advisors LLC. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include Gavin Wood, Lawrence M Alleva, and Peter W Sonsini. View insider buying and selling activity for Adaptimmune Therapeutics. How do I buy shares of Adaptimmune Therapeutics? Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Adaptimmune Therapeutics' stock price today? One share of ADAP stock can currently be purchased for approximately $10.43. How big of a company is Adaptimmune Therapeutics? Adaptimmune Therapeutics has a market capitalization of $1.36 billion and generates $1.12 million in revenue each year. The biotechnology company earns $-137,160,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. Adaptimmune Therapeutics employs 406 workers across the globe. What is Adaptimmune Therapeutics' official website? The official website for Adaptimmune Therapeutics is www.adaptimmune.com. How can I contact Adaptimmune Therapeutics? Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
